Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 14/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 1.00 |
| ▸ | GUSB | P08236 | 7/20 | 1.00 |
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | WNT3A | P56704 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900584 | 1.00 | TNKS (1.00) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL6885282 | 0.92 | TNKS (0.93) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL6124189 | 0.88 | TNKS (0.93) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL29592833 | 0.88 | TNKS (1.00) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL258433 | 0.88 | TNKS (1.00) | TNKSTNKS2GUSBPARP1PARP2 | |
| Hydrochloric Acid SCHEMBL31529601 | 0.86 | TNKS (0.96) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL15689534 | 0.86 | TNKS (0.75) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL16404347 | 0.84 | HDAC8 (0.75) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL7765127 | 0.84 | TNKS (1.00) | TNKSTNKS2GUSBPARP1PARP2 | |
| SCHEMBL8618982 | 0.84 | TNKS (1.00) | TNKSTNKS2GUSBPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010671-B | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-115028588-B | Green synthesis method of heterocyclic compound | 徐州医科大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-115028588-A | Green synthesis method of heterocyclic compound | 徐州医科大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-115010671-A | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2022-09-06 | — | — | CN | disclosed |
| WO-2017192691-A1 | CELL CULTURE CONTAINING BROMODOMAIN INHIBITORS | BIOGEN MA INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9758459-B2 | Allosteric modulators of factor XIa as anticoagulant agents | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311842-A1 | ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| CN-103880761-B | The method of one pot process 4 (3H)-Quinazol derivative is eliminated by cyclization | TIANJIN UNIVERSITY (CN) | 2015-07-29 | — | — | CN | disclosed |
| CN-104447581-A | Method for synthesizing N-heterocyclic compound | UNIV HUNAN | 2015-03-25 | — | — | CN | disclosed |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2014-09-11 | — | — | US | disclosed |
| CN-103880761-A | Method for synthesizing 4(3H)-quinazolinone derivative by using cyclization elimination one-pot method | UNIV TIANJIN | 2014-06-25 | — | — | CN | disclosed |
| WO-2014087165-A1 | TANKYRASE INHIBITORS | UNIVERSITY OF BATH (GB) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014075045-A1 | ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-1960977-A | Quinazoline derivative | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | TNKS 2500/4885TNKS2 2374/4885GUSB 4791/4885 |
| US-20140256754-A1 | QUINAZOLINES AS B-GLUCURONIDASE NOVEL INHIBITORS | GUSB, GBA3, GAA | TNKS 1726/4885TNKS2 1674/4885GUSB 1/4885 |
| US-20160311842-A1 | ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS | TFPI, TFPI2, F10 | TNKS 3494/4885TNKS2 3527/4885GUSB 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.